Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure ( BETA )

Description

The primary purpose for this study is to support the hypothesis (pilot data) that the use of the CPM system reduces the rate of HF related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the primary objective, the study will compare the outcomes and costs for patients using the CPM system against those who are not. This can either be done using institutions averages, if available, or through a control group.

Conditions

Heart Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary purpose for this study is to support the hypothesis (pilot data) that the use of the CPM system reduces the rate of HF related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the primary objective, the study will compare the outcomes and costs for patients using the CPM system against those who are not. This can either be done using institutions averages, if available, or through a control group.

Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure ( BETA )

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Orlando

Orlando Health, Orlando, Florida, United States, 32806

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * NYHA Class III-IV
  • * NYHA Class II HF with one or more of the following:
  • * Chronic Kidney Disease (eGFR\<60 within the past 6 months)
  • * HF hospitalization (defined as HF listed as the major reason for hospitalization) within 9 months prior to screening visit and NT-proBNP \> 200 pg/ml for patients not in AF or \> 600 pg/m for patients in AF on screening ECG
  • * NT-proBNP \> 300 pg/ml for patients not in AF or \> 900 pg/ml for patients in AF on the screening visit ECG.
  • * Chronic obstructive pulmonary disease (COPD)
  • * Under 18 years of age
  • * Patients with severe COPD (GOLD stage III or IV)
  • * Limited mobility preventing application of device
  • * Cognitive impairments that would limit the application and proper use of the device
  • * Skin allergies or skin sensitivities to silicone-based adhesives
  • * Pregnancy
  • * Skin breakdown on the left chest or breast area
  • * Not willing to shave chest hair if needed to apply device
  • * Patients on chronic ionotropic therapy
  • * Patients with any condition that might limit the survival to less than 1 year as assessed by the investigator
  • * No cellular coverage (Patient's Home)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Analog Device, Inc.,

Study Record Dates

2025-11-01